Monika Schäfer-korting

Biography

1976-1977 Ph.D. thesis, Pharmakologisches Institut für Naturwissenschaftler, Goethe-Universität Frankfurt/M (Germany) with Prof. Dr. Dr. E. Mutschler 1978-79 Postdoctoral Fellow Institut für Pharmakologie und Toxikologie, Technische Universität München with Prof. Dr. M. Reiter 1980-92 Research associate at the Pharmakologisches Institut für Naturwissenschaftler, Goethe-Universität Frankfurt/M (Germany) with Prof. Dr. Dr. E. Mutschler 1992-94 Guest professor at the Institut für Pharmazie, Freie Universität Berlin since 1994 Full professor of Pharmacology at the Institut für Pharmazie, Freie Universität Berlin 1997-1999 Vice-President of the Freie Universität Berlin 2003 Elected Vice-President for Research of the University of Veterinary Medicine, Vienna (Austria; declined) 2003-2008 Speaker of the DFG research group 463 “Innovative drugs and carrier systems” since 2004 Board Member of the Ethics Committee of the University of Veterinary Medicine, Vienna (Austria) since 2004 Training Laboratory for Alternatives to Experiments in the Animal (EFRE funding) since 2005 Head of the Scientific Advisory Board of the Federal Institute for Risk Assessment, Berlin (Germany) 2006-2010 Member of the BMBF research group “NanoDerm” since 2007 Vice-President of the Freie Universität Berlin (Biosciences and Research) 2009-2011 Member of the BMBF research group “Skin Metabolism” 2010 (-2013) Member of the EU Coordination group “Accelerating the transition to a toxicity pathway-based paradigm for chemical safety assessment” (AXLR8) since 2012 Member of Helmholtz Viritual Institute “Functional Biomaterials for Medicine” News Pharmakologie und Toxikologie keine aktuellen Meldungen Termine keine aktuellen Termine Zur Übersicht

Research Interest

The focus is on the improvement of the therapy of skin diseases by testing potential new pharmaceuticals with regard to the skin, elucidating the molecular mechanisms of action of known and new drugs, investigating the uptake and metabolization of such substances in human skin, but also with the aid of two- and three-dimensional skin models Models of skin diseases and an increase in the benefit / risk ratio by means of particulate carrier systems